Medications Similar to Veozah for Hot Flashes
Critical Clarification: Veozah is NOT Transdermal Estradiol
Veozah (fezolinetant) is an oral non-hormonal neurokinin-3 receptor antagonist, not a transdermal estradiol product. 1 It represents a fundamentally different drug class from hormone therapy and works by modulating KNDy neurons in the hypothalamus rather than replacing estrogen. 2
Non-Hormonal Alternatives Similar to Veozah
For women seeking non-hormonal treatment like Veozah, the most effective alternatives are SSRIs (particularly paroxetine), SNRIs (venlafaxine), and gabapentin—all of which have demonstrated efficacy in reducing hot flash frequency and severity in controlled trials. 3, 4
Evidence-Based Non-Hormonal Options:
Paroxetine (SSRI): Shows greater reductions in hot flash frequency and severity compared to clonidine, with a more robust benefit than fluoxetine. 4 This is the only FDA-approved SSRI specifically for vasomotor symptoms.
Venlafaxine (SNRI): Demonstrates significant efficacy in reducing hot flashes, with superior results compared to clonidine in controlled trials. 4 Particularly well-studied in breast cancer patients on tamoxifen.
Gabapentin (GABA analog): Effectively alleviates hot flashes with demonstrated efficacy comparable to or exceeding clonidine. 3, 4 Part of the GABA analog class that has proven effectiveness for vasomotor symptoms.
Clonidine: Moderately effective in both oral and transdermal formulations, though generally less effective than the above options. 4
Hormonal Therapy Options (Different Class from Veozah)
If considering hormonal therapy instead of non-hormonal options like Veozah, systemic estrogen (with or without progestin) remains the gold standard for hot flash treatment—but this should only be initiated within 10 years of menopause and before age 60. 5
Critical Hormonal Therapy Restrictions:
Age and timing matter critically: Starting hormone therapy at age 64 or beyond markedly increases risks of stroke, dementia, and cardiovascular disease (Grade D recommendation against). 5
No dose-adjustment safety benefit: Lower-dose transdermal estradiol (0.025 mg) does not meaningfully change the risk-benefit profile in older women compared to standard doses. 5
"Bioidentical" hormones offer no safety advantage: The FDA states there is no evidence that natural or bioidentical estrogens have different risk profiles than synthetic estrogens at equivalent doses. 5
Not for chronic disease prevention: The USPSTF issues a Grade D recommendation (strong recommendation against) using combined estrogen-progestin or estrogen alone for preventing chronic conditions in postmenopausal women. 6, 5
Veozah-Specific Efficacy Data
Frequency reduction: Veozah 45 mg reduced moderate-to-severe hot flashes by 2.1-2.6 episodes per day at week 4 and 2.5-2.6 episodes at week 12 compared to placebo (p<0.001). 1
Severity reduction: Significant improvements in severity scores at both weeks 4 and 12 (p≤0.007). 1
Rapid onset: Improvements observed within 1 week and maintained over 52 weeks. 7
Safety Monitoring Requirements for Veozah
Mandatory liver monitoring: Blood tests required before starting, monthly for first 3 months, then at months 6 and 9. 1
Contraindications: Do not use in cirrhosis, severe kidney problems, or with CYP1A2 inhibitors. 1
Common adverse effects: Abdominal pain, diarrhea, insomnia, back pain, and paradoxically hot flushes. 1
Non-Pharmacologic Adjuncts
- Lifestyle modifications: Wear layered clothing, maintain cool sleeping environments, and avoid triggers including alcohol, spicy foods, and caffeine. 5 These measures provide moderate benefit based on consensus evidence.